The estimated Net Worth of Juan Graham is at least $334 Thousand dollars as of 7 June 2023. Mr Graham owns over 1,785 units of FibroGen Inc stock worth over $28,433 and over the last 3 years he sold FGEN stock worth over $305,200.
Mr has made over 4 trades of the FibroGen Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently he sold 1,785 units of FGEN stock worth $30,327 on 7 June 2023.
The largest trade he's ever made was selling 7,661 units of FibroGen Inc stock on 8 March 2023 worth over $157,357. On average, Mr trades about 1,158 units every 12 days since 2021. As of 7 June 2023 he still owns at least 71,083 units of FibroGen Inc stock.
You can see the complete history of Mr Graham stock trades at the bottom of the page.
Juan Graham is the Chief Financial Officer at FibroGen Inc.
Juan's mailing address filed with the SEC is C/O FIBROGEN, INC., 409 ILLINOIS STREET, SAN FRANCISCO, CA, 94158.
Over the last 10 years, insiders at FibroGen Inc have traded over $188,593,537 worth of FibroGen Inc stock and bought 106,523 units worth $1,309,423 . The most active insiders traders include Rory B Riggs, Thomas B Neff, and Jeffrey William Henderson. On average, FibroGen Inc executives and independent directors trade stock every 8 days with the average trade being worth of $6,963. The most recent stock trade was executed by Deyaa Adib on 12 June 2024, trading 22,123 units of FGEN stock currently worth $25,884.
fibrogen is a research-based biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics to treat serious unmet medical needs. the company has built upon its extensive research experience in fibrosis and hypoxia-inducible factor (hif) biology to generate clinical programs targeting multiple therapeutic areas. fibrogen's most advanced product candidate, roxadustat (fg-4592), is an oral small molecule inhibitor of hif prolyl hydroxylases (hif-phs), in phase 3 clinical development for the treatment of anemia in chronic kidney disease (ckd). our second product candidate, fg-3019, is a monoclonal antibody in phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (ipf), pancreatic cancer and liver fibrosis. for more information please visit: www.fibrogen.com.
FibroGen Inc executives and other stock owners filed with the SEC include: